Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Case Rep Cardiol ; 2022: 3621799, 2022.
Article in English | MEDLINE | ID: mdl-36544591

ABSTRACT

This case series demonstrates how COVID-19 infection might affect the heart in the context of acute myocardial infarction. Atrioventricular (AV) block might appear as one of the significant cardiac complications of acute MI in patients who tested COVID-19 PCR positive regardless of the presence of CVOID-19 infection symptoms. In our series, conduction disorders as a complication of acute inferior STEMI are more common in patients who tested positive for the COVID-19 infection. 11 patients out of 18 inferior STEMI patients who have tested positive for the COVID-19 infection have atrioventricular block disorders.

2.
Curr Probl Cardiol ; 47(7): 100956, 2022 Jul.
Article in English | MEDLINE | ID: mdl-34363847

ABSTRACT

A high-intensity statin is recommended for the secondary prevention of cardiovascular diseases (CVD). However, real-world evidence of the effectiveness of rosuvastatin following acute coronary syndrome (ACS) is scarce. This retrospective cohort study included patients diagnosed with ACS to compare between the 2 high-intensity statin therapies (rosuvastatin vs atorvastatin) in terms of a primary composite outcome of CVD-associated death, non-fatal ACS, and non-fatal stroke at 1 month and 12 months post discharge. The primary effectiveness outcome did not differ between the 2 groups at 1 month (1.3% vs 1%; aHR = 1.64, 95% CI 0.55-4.94, P= 0.379) and at 12 months (4.8% vs 3.5%; aHR = 1.48, 95% CI 0.82-2.67, P= 0.199). Similarly, the 2 groups had comparable safety outcomes. In conclusion, the use of high-intensity rosuvastatin compared to high-intensity atorvastatin therapy in patients with ACS had resulted in comparable cardiovascular effectiveness and safety outcomes.


Subject(s)
Acute Coronary Syndrome , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Acute Coronary Syndrome/diagnosis , Acute Coronary Syndrome/drug therapy , Aftercare , Atorvastatin/adverse effects , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Patient Discharge , Retrospective Studies , Rosuvastatin Calcium/adverse effects , Treatment Outcome
3.
Heart Views ; 22(4): 288-292, 2021.
Article in English | MEDLINE | ID: mdl-35330647

ABSTRACT

We present the case of a 38-year-old male with a history of acute chest pain associated with electrocardiographic ST-segment elevation and levels of myocardial damage markers. Few studies have evaluated chest pain and elevated troponin T during subacute thyroiditis. To the best of our knowledge, this is the reported case of myopericarditis associated with increased thyroid hormones in the bloodstream and accompanied by a significant increase in troponin T and cardiac magnetic resonance imaging findings of myopericarditis during the acute phase of subacute thyroiditis.

4.
Br J Clin Pharmacol ; 87(4): 2043-2052, 2021 04.
Article in English | MEDLINE | ID: mdl-33068036

ABSTRACT

AIMS: To compare the effectiveness and safety of 2 high-intensity atorvastatin doses (40 mg vs 80 mg) among acute coronary syndrome (ACS) patients. METHODS: This retrospective observational cohort study using real-world data included patients admitted with ACS to the Heart Hospital in Qatar between 1 January 2017 and 31 December 2018. The primary endpoint was a composite of cardiovascular disease-associated death, nonfatal ACS and nonfatal stroke. Cox proportional hazard regression analysis was used to determine the association between the 2 high-intensity atorvastatin dosing regimens and the primary outcome at 1 month and 12 months postdischarge. RESULTS: Of the 626 patients included in the analyses, 475 (75.9%) received atorvastatin 40 mg, while 151 (24.1%) received atorvastatin 80 mg following ACS. Most of the patients were Asian (73%), male (97%) with a mean age of 50 years and presented with ST-elevation myocardial infarction (60%). The incidence of the primary effectiveness outcome did not differ between the atorvastatin 40-and 80-mg groups at 1 month (0.8 vs 1.3%; adjusted hazard ratio = 0.59, 95% confidence interval 0.04-8.13, P = .690) and at 12 months (3.2 vs 4%; adjusted hazard ratio = 0.57, 95% confidence interval 0.18-1.80, P = .340). Similarly, the use of the 2 doses of atorvastatin resulted in comparable safety outcomes, including liver toxicity, myopathy and rhabdomyolysis with an event rate of <1% in both groups. CONCLUSION: The use of atorvastatin 40 mg in comparison to atorvastatin 80 mg in patients with ACS resulted in similar cardiovascular effectiveness and safety outcomes.


Subject(s)
Acute Coronary Syndrome , Acute Coronary Syndrome/drug therapy , Aftercare , Atorvastatin/adverse effects , Humans , Male , Middle Aged , Patient Discharge , Retrospective Studies
5.
Heart Views ; 21(1): 40-44, 2020.
Article in English | MEDLINE | ID: mdl-32082500

ABSTRACT

De winter pattern on the ECG is associated with occlusion of proximal left anterior descending artery. It is an atypical presentation of acute myocardial infarction due to LAD occlusion. We report a case due to thromboembolic occlusion of LAD after chemical cardioversion. It is imperative for cardiologists and physicians to instantly identify the De Winter pattern on ECG to appropriately triage these patients without delay.

6.
Heart Views ; 18(3): 83-87, 2017.
Article in English | MEDLINE | ID: mdl-29184614

ABSTRACT

Idiopathic left fascicular ventricular tachycardia (ILFVT) is characterized by right bundle branch block morphology and left axis deviation. We report a case of idiopathic left ventricular fascicular tachycardia in a young 31-year-old male patient presenting with a narrow complex tachycardia.

SELECTION OF CITATIONS
SEARCH DETAIL
...